tiprankstipranks
Trending News
More News >
Spago Nanomedical AB (SE:SPAGO)
:SPAGO
Sweden Market
Advertisement

Spago Nanomedical AB (SPAGO) Drug Pipeline

Compare
0 Followers
Drug Name
Condition
Stage
Status
Study Name
Trial Start Date
Article
[177Lu]Lu-Sn201
Solid Tumor, Recurrent Solid Tumor, Locally Advanced Solid Tumor, Metastatic Cancer, Refractory Cancer, Unresectable Solid Tumor
Phase I/II
Recruiting
A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer
Dec 06, 2023
Sn132d
Endometriosis
Phase II
Completed
Efficacy of SN132D in Patients With Suspected Endometriosis
Dec 07, 2022
Sn132d
Breast Cancer, Pancreas Cancer
Phase I
Completed
A First-in-human Clinical Evaluation of SN132D in Patients With Breast and Pancreatic Cancer
Aug 27, 2019

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
    What is a clinical trial?
    A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
      What drugs does Spago Nanomedical AB (SPAGO) have in its pipeline
      SPAGO is currently developing the following drugs: [177Lu]Lu-Sn201, Sn132d, Sn132d. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis